Susan J. Tofte

TL;DR: In this paper, the reliability of the EASI scoring system was evaluated by assessing inter-and intra-observer consistency, and the results indicated that the evaluators assessed the patients consistently across both study days.

TL;DR: This study of childhood AD frequency indicates a high prevalence of AD in the United States, comparable to that recently observed from studies in Europe and Japan.

TL;DR: This study demonstrated that rIFN-gamma given by daily subcutaneous injection over a 12-week period was safe, well accepted, and effective in reducing inflammation, clinical symptoms, and eosinophilia in severe atopic dermatitis.

TL;DR: In vitro assays demonstrated the ability of selective high-potency phosphodiesterase inhibitors to reduce prostaglandin E2, IL-10, and IL-4 production in atopic mononuclear leukocyte cultures, and this in vivo demonstration of anti-inflammatory efficacy may provide a useful alternative to the over-reliance on corticosteroid therapy inAtopic disease.

TL;DR: Treating physicians should be aware of associations in seeking to alleviate the burden for patients with atopic dermatitis and to improve patient outcomes and to help mitigate the cost and burdens associated with these conditions.